KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to -$12.4 million.

  • Twist Bioscience's Change in Accured Expenses fell 494.51% to -$12.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.0 million, marking a year-over-year increase of 44632.82%. This contributed to the annual value of $6.6 million for FY2025, which is 1603.81% down from last year.
  • According to the latest figures from Q4 2025, Twist Bioscience's Change in Accured Expenses is -$12.4 million, which was down 494.51% from $1.1 million recorded in Q3 2025.
  • Twist Bioscience's 5-year Change in Accured Expenses high stood at $14.1 million for Q2 2025, and its period low was -$12.9 million during Q3 2022.
  • Moreover, its 5-year median value for Change in Accured Expenses was $2.0 million (2024), whereas its average is $397700.0.
  • As far as peak fluctuations go, Twist Bioscience's Change in Accured Expenses skyrocketed by 116523.08% in 2021, and later plummeted by 56159.06% in 2022.
  • Quarter analysis of 5 years shows Twist Bioscience's Change in Accured Expenses stood at -$3.6 million in 2021, then fell by 2.54% to -$3.7 million in 2022, then crashed by 36.65% to -$5.1 million in 2023, then tumbled by 133.36% to -$11.8 million in 2024, then decreased by 4.95% to -$12.4 million in 2025.
  • Its last three reported values are -$12.4 million in Q4 2025, $1.1 million for Q3 2025, and $14.1 million during Q2 2025.